Click for best price
Postpemic Era NonAlcoholic Steatohepatitis NASH Drugs Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Non-Alcoholic Steatohepatitis (NASH) Drugs industry at home and abroad, estimate the overall market scale of the Non-Alcoholic Steatohepatitis (NASH) Drugs industry and the market share of major countries, Non-Alcoholic Steatohepatitis (NASH) Drugs industry, and study and judge the downstream market demand of Non-Alcoholic Steatohepatitis (NASH) Drugs through systematic research, Analyze the competition pattern of Non-Alcoholic Steatohepatitis (NASH) Drugs, so as to help solve the pain points of various stakeholders in Non-Alcoholic Steatohepatitis (NASH) Drugs industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Non-Alcoholic Steatohepatitis (NASH) Drugs Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Non-Alcoholic Steatohepatitis (NASH) Drugs Market?
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
Major Type of Non-Alcoholic Steatohepatitis (NASH) Drugs Covered in XYZResearch report:
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Application Segments Covered in XYZResearch Market
Hospital Pharmacy
Online Provider
Retail Pharmacy
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
82 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Value
2.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type
2.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Value
2.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Sales
2.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Type
2.3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Sales
3. The Major Driver of Non-Alcoholic Steatohepatitis (NASH) Drugs Industry
3.1 Historical & Forecast Global Non-Alcoholic Steatohepatitis (NASH) Drugs Sales and Revenue (2018-2028)
3.2 Largest Application for Non-Alcoholic Steatohepatitis (NASH) Drugs (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Non-Alcoholic Steatohepatitis (NASH) Drugs Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Non-Alcoholic Steatohepatitis (NASH) Drugs Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Average Price Trend
13.1 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in US (2018-2022)
13.2 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Europe (2018-2022)
13.3 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in China (2018-2022)
13.4 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Japan (2018-2022)
13.5 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in India (2018-2022)
13.6 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Korea (2018-2022)
13.7 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Non-Alcoholic Steatohepatitis (NASH) Drugs
15. Non-Alcoholic Steatohepatitis (NASH) Drugs Competitive Landscape
15.1 AstraZeneca
15.1.1 AstraZeneca Company Profiles
15.1.2 AstraZeneca Product Introduction
15.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Conatus Pharmaceuticals
15.2.1 Conatus Pharmaceuticals Company Profiles
15.2.2 Conatus Pharmaceuticals Product Introduction
15.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Enzo Biochem
15.3.1 Enzo Biochem Company Profiles
15.3.2 Enzo Biochem Product Introduction
15.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Galmed Pharmaceuticals
15.4.1 Galmed Pharmaceuticals Company Profiles
15.4.2 Galmed Pharmaceuticals Product Introduction
15.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Genfit
15.5.1 Genfit Company Profiles
15.5.2 Genfit Product Introduction
15.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Gilead
15.6.1 Gilead Company Profiles
15.6.2 Gilead Product Introduction
15.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Horizon Pharma
15.7.1 Horizon Pharma Company Profiles
15.7.2 Horizon Pharma Product Introduction
15.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Immuron
15.8.1 Immuron Company Profiles
15.8.2 Immuron Product Introduction
15.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 Intercept Pharmaceuticals
15.9.1 Intercept Pharmaceuticals Company Profiles
15.9.2 Intercept Pharmaceuticals Product Introduction
15.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 Novo Nordisk
15.10.1 Novo Nordisk Company Profiles
15.10.2 Novo Nordisk Product Introduction
15.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Non-Alcoholic Steatohepatitis (NASH) Drugs Industry (Volume)
Figure 2. Non-Alcoholic Steatohepatitis (NASH) Drugs Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2022
Figure 5. US Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, by Type (Million USD) (2018-2028)
Table 4. Non-Alcoholic Steatohepatitis (NASH) Drugs Sales, by Type (K Unit) (2018-2028)
Table 5. Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Unit) by Application (2018-2028)
Table 6. Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Non-Alcoholic Steatohepatitis (NASH) Drugs in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. AstraZeneca Profiles
Table 61. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product Introduction
Table 62. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. AstraZeneca Strategic initiatives
Table 64. Conatus Pharmaceuticals Profiles
Table 65. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Introduction
Table 66. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Conatus Pharmaceuticals Strategic initiatives
Table 68. Enzo Biochem Profiles
Table 69. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product Introduction
Table 70. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Enzo Biochem Strategic initiatives
Table 72. Galmed Pharmaceuticals Profiles
Table 73. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Introduction
Table 74. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Galmed Pharmaceuticals Strategic initiatives
Table 76. Genfit Profiles
Table 77. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product Introduction
Table 78. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Genfit Strategic initiatives
Table 80. Gilead Profiles
Table 81. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product Introduction
Table 82. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Gilead Strategic initiatives
Table 84. Horizon Pharma Profiles
Table 85. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product Introduction
Table 86. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Horizon Pharma Strategic initiatives
Table 88. Immuron Profiles
Table 89. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product Introduction
Table 90. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Immuron Strategic initiatives
Table 92. Intercept Pharmaceuticals Profiles
Table 93. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product Introduction
Table 94. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Intercept Pharmaceuticals Strategic initiatives
Table 97. Novo Nordisk Profiles
Table 98. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product Introduction
Table 99. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Novo Nordisk Strategic initiatives
